Results 61 to 70 of about 2,891 (162)

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, Volume 20, Issue 7, Page 1694-1712, July 2026.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, Volume 101, Issue 7, Page 1433-1439, July 2026.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

Journal of Hematology & Oncology, 2018
Background Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single agent, as well ...
Amy Y. Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew S. Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu   +16 more
doaj   +1 more source

CRISPR‐Cas9 Genome‐Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies

Medicinal Research Reviews, Volume 46, Issue 4, Page 989-1004, July 2026.
ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He, Patrick Connerty, Antoine de Weck   +2 more
wiley   +1 more source

Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database

Scientific Reports
As the world's first oral nuclear export inhibitor, selinexor is increasingly being used in clinical applications for malignant tumors. However, there is no extensive exploration on selinexor's adverse events (ADEs), necessitating a real-word assessment ...
Yi Liu, Runyu Yang, Hui Feng, Yue Du, Bingyu Yang, Mengyao Zhang, Pengcheng He, Bohan Ma, Fan Niu   +8 more
doaj   +1 more source

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

Haematologica, 2018
Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K ...
Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo, Sharon Shacham, Naval Daver, Michael Andreeff   +7 more
doaj   +1 more source

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine

Frontiers in Oncology
BackgroundAtypical chronic myeloid leukemia (aCML) is a BCR::ABL1 negative myelodysplastic/myeloproliferative neoplasm with poor overall survival.
Lu Liu, Xiaofeng Song, Wenhao Dong, Zhao Li, Dongmei Guo   +4 more
doaj   +1 more source

Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor

Current Oncology
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education.
Lucio N. Gordan, David Ray, Stephen C. Ijioma, George Dranitsaris, Amanda Warner, Trevor Heritage, Matthew Fink, David Wenk, Paul Chadwick, Natasha Khrystolubova, Shachar Peles   +10 more
doaj   +1 more source

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

Oncotarget, 2016
Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced cancers. In this study, we evaluated the effects of selinexor in several preclinical models of various sarcoma subtypes.
Nakayama, Robert, Sicinska, Ewa, Fletcher, Jonathan, Demetri, George, Wagner, Andrew, Zhang, Yi-Xiang, Czaplinski, Jeffrey T., Anatone, Alex J.   +7 more
openaire   +5 more sources

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma

Cancer, Volume 132, Issue 14, 15 July 2026.
Heidi A. Worth, Luciano J. Costa
wiley   +1 more source